Effective coronavirus reduction by various production steps during the manufacture of plasma-derived medicinal products

Tobias Schräder; Julia Koch; Rachael Ross; Wolfram Schäfer; Björn Keiner; Nathan J Roth; Eleonora Widmer

doi:10.1111/trf.15850

Effective coronavirus reduction by various production steps during the manufacture of plasma-derived medicinal products

Transfusion. 2020 Jun;60(6):1334-1335. doi: 10.1111/trf.15850.

Authors

Tobias Schräder^{1

2}, Julia Koch^{1

2}, Rachael Ross^{1

3}, Wolfram Schäfer^{1

2}, Björn Keiner^{1

2}, Nathan J Roth^{1

4}, Eleonora Widmer^{1

4}

Affiliations

¹ Global Pathogen Safety (GPS), CSL Behring, USA.
² CSL Behring GmbH, Marburg, Germany.
³ CSL Behring (Australia) Pty Ltd, Broadmeadows, Victoria, Australia.
⁴ CSL Behring AG, Bern, Switzerland.

No abstract available

Publication types

Letter

MeSH terms

Animals
Betacoronavirus / physiology
Biological Products / chemical synthesis*
Biological Products / isolation & purification
Drug Contamination / prevention & control
Humans
Hydrogen-Ion Concentration
Immunoglobulins, Intravenous / biosynthesis
Immunoglobulins, Intravenous / isolation & purification
Manufactured Materials / virology*
Pasteurization / methods
Pharmaceutical Preparations / chemical synthesis*
Pharmaceutical Preparations / isolation & purification
Plasma / chemistry*
Plasma / virology
SARS-CoV-2
Safety Management / methods
Safety Management / standards
Swine / virology
Transmissible gastroenteritis virus / physiology*
Treatment Outcome
Virus Inactivation*

Substances

Biological Products
Immunoglobulins, Intravenous
Pharmaceutical Preparations